United Therapeutics Corporation Increase (Decrease) in Accounts Payable
United Therapeutics Corporation (UTHR) reported Increase (Decrease) in Accounts Payable of -$780.00 thousand for the 6-month period ending 2013-06-30, per its 10-Q filed 2013-07-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2013-07-25
- United Therapeutics Corporation increase (decrease) in accounts payable for the quarter ending 2013-06-30 was -$899.00K, a 313.03% decline year-over-year.
- United Therapeutics Corporation increase (decrease) in accounts payable for the quarter ending 2013-03-31 was $119.00K.
- United Therapeutics Corporation increase (decrease) in accounts payable for the quarter ending 2012-12-31 was $18.00K, a 99.88% decline year-over-year.
- United Therapeutics Corporation increase (decrease) in accounts payable for the quarter ending 2012-09-30 was $1.32M, a 788.59% increase year-over-year.
- United Therapeutics Corporation increase (decrease) in accounts payable for fiscal 2012 was -$37.21M, a 323.38% decline from fiscal 2011.
- United Therapeutics Corporation increase (decrease) in accounts payable for fiscal 2011 was $16.66M.
- United Therapeutics Corporation increase (decrease) in accounts payable for fiscal 2010 was -$2.73M.
- United Therapeutics Corporation increase (decrease) in accounts payable for fiscal 2009 was -$3.65M, a 119.69% decline from fiscal 2008.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2013-06-30 | -$899.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | -$780.00K 10-Q · filed 2013-07-25 | -$762.00K derived: sum of 3 quarters · filed 2013-07-25 | $562.00K derived: sum of 4 quarters · filed 2013-07-25 |
| 2013-03-31 | $119.00K 10-Q · filed 2013-04-25 | $137.00K derived: sum of 2 quarters · filed 2013-04-25 | $1.46M derived: sum of 3 quarters · filed 2013-04-25 | $1.88M derived: sum of 4 quarters · filed 2013-07-25 |
| 2012-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $1.34M derived: sum of 2 quarters · filed 2013-02-26 | $1.76M derived: sum of 3 quarters · filed 2013-07-25 | -$37.21M 10-K · filed 2013-02-26 |
| 2012-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $1.75M derived: sum of 2 quarters · filed 2013-07-25 | -$37.23M 10-Q · filed 2012-11-01 | -$21.61M derived: sum of 4 quarters · filed 2013-07-25 |
| 2012-06-30 | $422.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | -$38.55M 10-Q · filed 2013-07-25 | -$22.93M derived: sum of 3 quarters · filed 2013-07-25 | -$22.78M derived: sum of 4 quarters · filed 2013-07-25 |
| 2012-03-31 | -$38.97M 10-Q · filed 2013-04-25 | -$23.36M derived: sum of 2 quarters · filed 2013-04-25 | -$23.21M derived: sum of 3 quarters · filed 2013-04-25 | -$16.16M derived: sum of 4 quarters · filed 2013-04-25 |
| 2011-12-31 | $15.62M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $15.77M derived: sum of 2 quarters · filed 2013-02-26 | $22.81M derived: sum of 3 quarters · filed 2013-02-26 | $16.66M 10-K · filed 2013-02-26 |
| 2011-09-30 | $149.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $7.19M derived: sum of 2 quarters · filed 2012-11-01 | $1.04M 10-Q · filed 2012-11-01 | $5.76M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $7.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $891.00K 10-Q · filed 2012-07-26 | $5.61M derived: sum of 3 quarters · filed 2013-02-26 | $7.49M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | -$6.15M 10-Q · filed 2012-04-26 | -$1.43M derived: sum of 2 quarters · filed 2013-02-26 | $445.00K derived: sum of 3 quarters · filed 2013-02-26 | $2.75M derived: sum of 4 quarters · filed 2013-02-26 |
| 2010-12-31 | $4.72M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $6.59M derived: sum of 2 quarters · filed 2013-02-26 | $8.89M derived: sum of 3 quarters · filed 2013-02-26 | -$2.73M 10-K · filed 2013-02-26 |
| 2010-09-30 | $1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $4.18M derived: sum of 2 quarters · filed 2011-10-27 | -$7.45M 10-Q · filed 2011-10-27 | -$8.37M derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-06-30 | $2.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | -$9.33M 10-Q · filed 2011-07-28 | -$10.25M derived: sum of 3 quarters · filed 2012-02-28 | -$2.77M derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-03-31 | -$11.63M 10-Q · filed 2011-04-28 | -$12.55M derived: sum of 2 quarters · filed 2012-02-28 | -$5.07M derived: sum of 3 quarters · filed 2012-02-28 | |
| 2009-12-31 | -$922.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $6.56M derived: sum of 2 quarters · filed 2012-02-28 | -$3.65M 10-K · filed 2012-02-28 | |
| 2009-09-30 | $7.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | -$2.72M 10-Q · filed 2010-10-28 | ||
| 2009-06-30 | -$10.20M 10-Q · filed 2010-07-28 | |||
| 2008-12-31 | $18.51M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |